How GLP-1 medicines changed the questions bariatric patients ask AI
Many patients who once would have started with a surgical consult now start on a GLP-1 medicine. The questions they later ask AI apps are different, and most surgical center sites do not answer them.
This is an opinion piece, not a study. It describes a shift in the questions patients ask, not measured consult volumes.
A patient who might have looked into a sleeve gastrectomy a few years ago is now more likely to start a GLP-1 medicine first, often through telehealth. Some of those patients come to a surgical center later, after a plateau, side effects or stopping treatment.
That changes the questions. Instead of "is gastric sleeve right for me", the questions become "what are my options if semaglutide stops working", "can I have surgery after stopping tirzepatide" or "revision surgery after a sleeve". Many surgical center sites were written for the first question and say little about the others.
The practical step is to answer those later questions directly on the center's own pages: who is eligible, how medication history affects the plan, what the surgeon's experience is with revision cases, and what the costs and insurance position are. Specific, accurate answers give patients and AI apps something concrete to repeat.
Whether AI apps then name the center is a separate, measurable question. We measure it with repeated runs of real patient questions on each AI app, reported per app.